Qiagen Ramping Up Production of RNA Extraction Kits for COVID-19 Detection, an Industrial Info Market Brief
Qiagen Ramping Up Production of RNA Extraction Kits for COVID-19 Detection, an Industrial Info Market Brief
Qiagen is working around the clock at its global manufacturing facilities to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19.
In Germantown, Maryland, where test kits are now being assembled 24/7, an approximately 188,000-square-foot expansion is in the works and awaiting permit approval to increase research and development and production capacity. Thermo Fisher Scientific has agreed to acquire Qiagen, and the transaction is expected to be completed in the first half of 2021.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Moderna Advances U.K. Vaccine Plant After Government Deal
- Ireland's Pharma Sector Boosted by New Investments
- West Coast, New England Lead in Life Science Capital Projects
- Industrial Manufacturing Leads Michigan to $7.5 Billion in Projects
- Fujifilm Diosynth Investing $1.6 Billion in Denmark and Texas Plants